Sunnyside Expands Alcohol Use Disorder Treatments with Innovative GLP-1 Options

Transforming Alcohol Use Disorder Treatment: Sunnyside's New GLP-1 Options

Sunnyside, a pioneering company in Alcohol Use Disorder (AUD) treatment, is making waves in the healthcare sector by introducing innovative GLP-1 options to its medication program. This initiative comes after the company successfully treated over 15,000 individuals within just 18 months of launching its Sunnyside Med program, which combines medication with comprehensive support services.

The newly launched programs integrate semaglutide, a GLP-1 medication, with naltrexone, an FDA-approved treatment for alcohol dependence, creating a dual approach for those seeking to reduce their alcohol intake or quit altogether. While medications for AUD have existed for years, they have remained largely underutilized. Statistically, a staggering 27.1 million U.S. adults were diagnosed with alcohol use disorder in 2024, yet only 2.4% received medication, underscoring the healthcare industry's need for proactive solutions.

Traditionally, treatment for AUD has been reactive rather than preventative, often initiated at least 8 to 10 years after the onset of Alcohol Use Disorder. Furthermore, medication adherence has been problematic; research indicates that only 25% of individuals starting oral naltrexone continue their prescriptions after 90 days, highlighting a critical gap in treatment efficacy.

Sunnyside founded its Med program to address these issues head-on, advocating for early intervention and proactive measures. By prioritizing medication as a first-line treatment rather than a last resort, Sunnyside boasts a significant increase in patient adherence rates compared to clinical benchmarks. In their naltrexone program, members refill their prescriptions at a rate 1.5 times higher than expected, and 88% of participants reported fewer heavy-drinking days after just 12 weeks. This success sets a strong foundation for the new GLP-1 integrations.

Nick Allen, Sunnyside's co-founder and CEO, noted, "Since launching Sunnyside Med, we've seen explosive demand for medically assisted treatment options. It's evident that while medication can manage cravings, it doesn't replace the need for support in changing drinking habits. This is precisely where Sunside's comprehensive care program makes a difference."

The addition of GLP-1 medications represents an exciting evolution in treatment, especially since GLP-1s have revolutionized obesity management by providing individuals with effective tools to control their weight. Sunnyside is confident that these medications will serve a similar purpose in Alcohol Use Disorder treatment. Recent studies, including a landmark clinical trial published in The Lancet, illustrate that adults with both AUD and obesity who received GLP-1 treatments experienced a marked reduction in heavy drinking days, reinforcing the potential of this dual-therapy approach.

Dr. Hrishikesh Belani, a Primary Care Physician and member of Sunnyside's Clinical Advisory Board, expressed optimism over GLP-1 medications, especially for individuals with comorbid obesity. He reaffirmed that ongoing support is crucial to achieving lasting treatment outcomes, citing, "The initial evidence for GLP-1 efficacy in reducing heavy alcohol consumption is promising. As providers begin to prescribe GLP-1 for alcohol treatment, sustained support will ensure success. This is the hallmark of Sunnyside Med."

The new GLP-1 + Naltrexone Microdose Program will cost $199 a month, while the Full Dose Program is priced at $299. A one-time intake fee of $50 applies, and specific BMI requirements are pertinent to each program. These medications are distributed as 84-day supplies, with check-ins with healthcare providers necessary for refill shipments. A standalone naltrexone option remains available for $99 per month, with no insurance necessary to access these services.

Currently, these innovative programs are available for individuals in all 50 states and Washington, D.C. at Sunnyside's website.

It’s crucial to note that while semaglutide is not specifically FDA-approved for treating Alcohol Use Disorder, the compounded medications provided through Sunnyside Med are managed by licensed U.S. pharmacies. Additionally, full safety information regarding the use of these medications is accessible on their website.

In summary, Sunnyside's innovative approach combines state-of-the-art medication strategies with robust support systems, positioning the company at the forefront of Alcohol Use Disorder treatment. As the landscape of alcohol dependence evolves, the integration of GLP-1 medications offers hope to many striving to reframe their relationship with alcohol.